SELLAS Life Sciences Group, Inc.
$4.99
▼
-1.9%
2026-04-21 09:28:01
sellaslifesciences.com
NCM: SLS
Explore SELLAS Life Sciences Group, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$896.12 M
Current Price
$4.99
52W High / Low
$6.14 / $1.26
Stock P/E
—
Book Value
$0.46
Dividend Yield
—
ROCE
-39.64%
ROE
-66.88%
Face Value
—
EPS
$-0.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
2.23
Debt / Equity
1.41
Current Ratio
10.72
Quick Ratio
10.72
Forward P/E
-26.44
Price / Sales
—
Enterprise Value
$784.02 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$8.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Absci Corporation | $3.95 | — | $547.82 M | — | -64.8% | -62.5% | $5.23 / $2.24 | $1.25 |
| 2. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
| 3. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
| 4. | Neurogene Inc. | $27.74 | — | $432.03 M | — | -37.96% | -31.41% | $37.27 / $10.46 | $17.1 |
| 5. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
| 6. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
| 7. | Editas Medicine, Inc. | $3.57 | — | $349.4 M | — | -70.81% | -1.98% | $4.54 / $1.23 | $0.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -8.26 M | -7.08 M | -6.87 M | -6.06 M | -6.92 M | — |
| Net Profit | -7.66 M | -6.79 M | -6.6 M | -5.81 M | -6.74 M | — |
| EPS in Rs | -0.04 | -0.04 | -0.04 | -0.03 | -0.04 | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 1 M |
| Operating Profit | -28.27 M | -31.51 M | -37.87 M | -31.95 M |
| Net Profit | -26.86 M | -30.88 M | -37.34 M | -41.3 M |
| EPS in Rs | -0.15 | -0.17 | -0.21 | -0.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 78.34 M | 19.43 M | 6.22 M | 20.94 M |
| Total Liabilities | 7.47 M | 9.97 M | 14.2 M | 16.09 M |
| Equity | 70.87 M | 9.46 M | -7.98 M | 4.85 M |
| Current Assets | 75.21 M | 16.33 M | 3.17 M | 17.76 M |
| Current Liabilities | 7.02 M | 9.51 M | 13.73 M | 15.52 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -28.39 M | -35.4 M | -31.41 M | -23.81 M |
| Investing CF | — | 0 M | -5.5 M | -4.5 M |
| Financing CF | 86.3 M | 46.76 M | 22.32 M | 24.08 M |
| Free CF | -28.39 M | -35.4 M | -36.91 M | -28.31 M |
| Capex | — | — | -5.5 M | -4.5 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 17.3% | 9.59% | — | — |
| Profit Margin % | — | — | -4130.1% | — |
| Operating Margin % | — | — | -3195% | — |
| Gross Margin % | — | — | 90% | — |
| EBITDA Margin % | — | — | -3195% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.